140 related articles for article (PubMed ID: 12883039)
1. Sequence specificity of adriamycin-DNA adducts in human tumor cells.
Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
Mol Cancer Ther; 2003 Jul; 2(7):661-70. PubMed ID: 12883039
[TBL] [Abstract][Full Text] [Related]
2. Barminomycin functions as a potent pre-activated analogue of Adriamycin.
Moufarij MA; Cutts SM; Neumann GM; Kimura K; Phillips DR
Chem Biol Interact; 2001 Nov; 138(2):137-53. PubMed ID: 11672697
[TBL] [Abstract][Full Text] [Related]
3. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
Cutts SM; Nudelman A; Pillay V; Spencer DM; Levovich I; Rephaeli A; Phillips DR
Oncol Res; 2005; 15(4):199-213. PubMed ID: 17822280
[TBL] [Abstract][Full Text] [Related]
4. The power and potential of doxorubicin-DNA adducts.
Cutts SM; Nudelman A; Rephaeli A; Phillips DR
IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
[TBL] [Abstract][Full Text] [Related]
5. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.
Cutts SM; Swift LP; Pillay V; Forrest RA; Nudelman A; Rephaeli A; Phillips DR
Mol Cancer Ther; 2007 Apr; 6(4):1450-9. PubMed ID: 17431124
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
Cutts SM; Rephaeli A; Nudelman A; Hmelnitsky I; Phillips DR
Cancer Res; 2001 Nov; 61(22):8194-202. PubMed ID: 11719450
[TBL] [Abstract][Full Text] [Related]
7. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase.
Cutts SM; Parsons PG; Sturm RA; Phillips DR
J Biol Chem; 1996 Mar; 271(10):5422-9. PubMed ID: 8621397
[TBL] [Abstract][Full Text] [Related]
8. Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.
Cutts SM; Rephaeli A; Nudelman A; Ugarenko M; Phillips DR
Curr Top Med Chem; 2015; 15(14):1409-22. PubMed ID: 25866273
[TBL] [Abstract][Full Text] [Related]
9. Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron.
Taatjes DJ; Gaudiano G; Koch TH
Chem Res Toxicol; 1997 Sep; 10(9):953-61. PubMed ID: 9305576
[TBL] [Abstract][Full Text] [Related]
10. Structural requirements for the formation of anthracycline-DNA adducts.
Cutts SM; Parker BS; Swift LP; Kimura KI; Phillips DR
Anticancer Drug Des; 2000 Oct; 15(5):373-86. PubMed ID: 11354313
[TBL] [Abstract][Full Text] [Related]
11. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
Taatjes DJ; Gaudiano G; Resing K; Koch TH
J Med Chem; 1997 Apr; 40(8):1276-86. PubMed ID: 9111302
[TBL] [Abstract][Full Text] [Related]
12. Formation of DNA adducts by formaldehyde-activated mitoxantrone.
Parker BS; Cullinane C; Phillips DR
Nucleic Acids Res; 1999 Jul; 27(14):2918-23. PubMed ID: 10390534
[TBL] [Abstract][Full Text] [Related]
13. Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.
Swift LP; Cutts SM; Rephaeli A; Nudelman A; Phillips DR
Mol Cancer Ther; 2003 Feb; 2(2):189-98. PubMed ID: 12589036
[TBL] [Abstract][Full Text] [Related]
14. Characterization of covalent adriamycin-DNA adducts.
Zeman SM; Phillips DR; Crothers DM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11561-5. PubMed ID: 9751705
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
16. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.
Coldwell KE; Cutts SM; Ognibene TJ; Henderson PT; Phillips DR
Nucleic Acids Res; 2008 Sep; 36(16):e100. PubMed ID: 18632763
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.
Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):431-47. PubMed ID: 16178771
[TBL] [Abstract][Full Text] [Related]
18. Sequence specificity of (cyanomorpholino)adriamycin adducts in human cells.
Cullinane C; Phillips DR
Biochemistry; 1994 May; 33(20):6207-12. PubMed ID: 8193134
[TBL] [Abstract][Full Text] [Related]
19. Detection of adriamycin-DNA adducts by accelerator mass spectrometry.
Coldwell K; Cutts SM; Ognibene TJ; Henderson PT; Phillips DR
Methods Mol Biol; 2010; 613():103-18. PubMed ID: 19997880
[TBL] [Abstract][Full Text] [Related]
20. Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.
Parker BS; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Oncol Res; 2004; 14(6):279-90. PubMed ID: 15206490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
